Phivida Holdings Inc (CSE:VIDA) reports the inaugural mass scale production of Phivida’s Nano-CBD™ infused functional foods, beverages and natural health products in preparation of a state-wide roll-out into the California retail market.

Phivida Nutrition produces Nano-CBD™ hemp oil infused beverages with a proprietary blend of phytonutraceuticals, including three flavours of Iced Teas, Vitamin Juices (Focus, Protect and Relax) and Vitamin Shots. Phivida Enhanced products include clinical grade sublingual’s, and a new specialty muscle, bone joint hard-cap pill both sold under the Vida+ label. A total of fifteen product skus are now slotted for manufacturing.


Mass production of Phivida’s CBD infused beverages will yield over 135,000 total units in inventory, including fifteen thousand finished packaged units for each sku of Nano-CBD™ hemp oil infused Vitamin Juices, Iced Teas and Vitamin Shots. Phivida is currently producing 5,000 units of CBD sublingual’s, and 5,000 units of its new CBD infused capsules for muscle, bone and joint pain. When combined, Phivida’s inaugural mass scale production will yield a total estimated wholesale inventory value of $2,500,000 USD.

Phivida is also pleased to announce the appointment of its new Vice President of Operations and Sales, Mr. Graham Magee. Mr. Magee is the former CEO of Full Spectrum CBD and the former US operating President of Endoca LLC. Mr. Magee will be managing the procurement and logistics of packaging and raw goods ingredient supply and overseeing mass production at Phivida’s cGMP and organic certified contract manufacturing facilities.

Green Reef LLC is also overseeing mass production, logistics and distribution. Green Reef is Phivida’s preferred Californiadistribution partner, and CEO Mr. Gagliardi is the former COO of Hansen’s Beverage (i.e. Monster Energy Drink), former Vice President and General Manager of Labatt’s USA (now Interbrew / InBev), and led Colgate Palmolive Canada for 15 years as the Vice President and General Manager. Green Reef has over fifteen captive sales and merchandising representatives in the field across California and has already begun advanced marketing and pre-sales of Phivida branded products to regional distributors and retail locations across the state.

Phivida’s production process includes; procurement, logistics and safety testing of all raw ingredients and packaging components to cGMP co-packer facilities. Quality assurance and safety testing will be performed via third party laboratory tested for potency, terpenes and safety. Upon release of a certificate of analysis verifying premium quality standards, proprietary formulas will be blended (“premixed”), and fed into a mass-scale bottling lines to be; filled, labelled, and packaged. Master cartons will be loaded onto pallets and sent to central distribution centres in southern and northern California for JIT fulfillment to retail stores and regional distributors.

Phivida Nano-CBD™ infused Hemp oil infused products eligible for sale in mainstream stores such as CVS, Rexall, Walgreens, Wholefoods, Sprouts and others. Phivida Holdings Inc. is focused on producing inventory for Californiadistribution partners. Production for export to global distribution networks in JapanAustralia and Germany through Asayake distribution and Phivida’s global on-line ecommerce affiliate partners, Namaste Technologies Inc. is planned for Q2 of 2018, with the primary focus on capturing leadership share of the California market.

The Phivida operations team launched large scale production this week to replenish stock distributor inventory and to prepare for a launch into California retail markets. Execution of large-scale food and beverage production cycles may range from 60 to 90 business days. The current production run was initiated in advance of receipt of funds from the initial public offering for an anticipated completion of April 15th to begin marketing and merchandising in prospective retail stores across California during the 2018 beverage season.

Phivida Holdings Inc.

Phivida (pronounced “fi-VEE-da”) is a premier brand of cannabidiol (“CBD”) infused functional foods, beverages and clinical products – poised for global distribution. Using nanoencapsulation technology, Phivida converts phytocannabinoids into water soluble delivery format, enhancing bioavailability, and timed released within the body. Phivida’s Nano-CBD™ is infused into functional beverages, foods and supplements containing a proprietary blend of phytonutraceuticals studied to target a range of health conditions, from chronic pain to terminal diseases. The World Anti-Doping Association’s recent decision to lift its ban of CBD from hemp oil and the World Health Organization’s recent statement supports the clinical benefits of CBD worldwide. Celebrating; Health and Wellness, In Harmony™, Phivida’s mission is to lead the alternative health care sector as the benchmark quality standard in premium cannabinoid infused foods, beverages and clinical products.  For more information on Phivida products visit www.phivida.com or join our social media network @Phivida. 

FORWARD-LOOKING INFORMATION

This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, the Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Click here to connect with Phivida Holdings Inc (CSE:VIDA) and receive an Investors Presentation.

Source: www.prnewswire.com

  • Company surpassed 5,600 patient prescriptions for its medical cannabis products in Colombia . Prescriptions filled increased over 450% in Q3 2020 over Q2 2020
  • Khiron declared a National Strategic Project by the Government of Colombia , simplifying and accelerating administration and processes for the Company in executing strategic projects in Colombia and for export
  • Subsequent to the quarter, the Company completed a bought deal financing on November 26, 2020 , selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000 CAD
  • Khiron signed partnerships with 15 clinics and health centres in Colombia , extending education and sales reach further across the country
  • As a result of the Company’s Doctor Zerenia TM telehealth platform more than 25% of the Company’s medical cannabis prescriptions came from outside of Bogota , expanding geographic presence of its Colombian clinics
  • Company achieved first sales of High CBD medical cannabis through private pharmacies in Peru . Additional approval received from Peru’s drug regulatory authority for Company’s High THC cannabis, with first prescriptions anticipated in Q1 2021
  • Expanded medical cannabis E-Learning platform to UK market in partnership with Medical Cannabis Clinicians Society (“MCCS”)
  • Entered an exclusive partnership with Rappi SAS, Latin America’s largest home multi-vertical app platform to distribute the Company’s CPG product portfolio, introducing Kuida products to Rappi users across the LatAm region
  • Signed agreement to distribute the Company’s Kuida TM CBD skincare brand through pharmacy, beauty retail and online markets serving the Hong Kong territory, with first orders expected in Q4 2020
  • Prudent cash use of $5 million in Q3 2020, compared with $4 million in Q2 2020, $12 million in Q1 2020 and $10 million in Q4 2019

 Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announced today its financial results for the quarter ended September 30, 2020 . These filings are available for review on the Company’s SEDAR profile at www.sedar.com All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less